Comparison · NCT02855450-sae
rhNGF vs Vehicle: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. rhNGF vs Vehicle: serious adverse events. Trial comparisons, record NCT02855450-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02855450-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.075 | 0.0258 | 0.199 | wilson | |
| Risk in group 2 | 0.1 | 0.0279 | 0.301 | wilson | |
| Risk difference, group 1 minus group 2 | -0.025 | -0.232 | 0.118 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.75 | 0.136 | 4.13 | log | |
| Odds ratio, group 1 over group 2 | 0.73 | 0.112 | 4.76 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on rhNGF than on Vehicle | 40 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: vehicle.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | rhNGF | rhNGF (Recombinant Human Nerve Growth Factor) 180 μg/ml eye drops solution~rhNGF: Recombinant Human Nerve Growth Factor 180μg/ml (one 35 μl drop equals to 6.30 μg of rhNGF) reconstituted solution three times a day (TID) for 8 weeks of treatment. | 3 | 40 | EG000 |
| Group 2 | Vehicle | Ophthalmic Placebo solution~Vehicle: Ophthalmic Placebo solution of the same composition as the test product with the exception of rhNGF reconstituted solution times a day (TID) for 8 weeks of treatment. | 2 | 20 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Treatment period: Day 0 (Therapy initiation), Day 7, Day 28, Day 56; Follow-up: Day 84, Day 224
Source ClinicalTrials.gov
Trial
- Title
- Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma
- NCT number
- NCT02855450
- Phases
- PHASE1
- Conditions
- Glaucoma
- Interventions
- rhNGF, Vehicle
- Lead sponsor
- Dompé Farmaceutici S.p.A
- Results first posted
- 2020-11-25
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02855450?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02855450-sae